Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
She has a proven track record of leading and mentoring start-ups in the biotechnology field, with her proven abilities in investment and portfolio management, investments, risk management, and business strategy development, Maria is a go-to expert in...
Biotech supply chains face an uncertain future in 2022 and beyond: up against myriad challenges ranging from future pandemic outbreaks to geopolitical tensions – and, indeed, unforeseen threats. Communication and collaboration between policymakers and...
The 32nd iteration of the company’s Beyond Borders report offers an in-depth look at the state of the current market landscape, and what’s on the horizon.
The pharmaceutical and biotech consultancy has opened a new office in Dublin, Ireland ahead of Brexit, the final outcomes of which remain unknown, says CEO.
Contract drug developer RxCelerate has opened an office in Massachusetts to expand its medicinal chemistry, antibody discovery, and preclinical safety services throughout North America.
SQI Diagnostics Inc. has signed an agreement to commercialize a custom multiplexed assay for a Waltham, MA-based global biotechnology company's blood disorder drug program.
IndieBio has teamed up with Science Exchange’s network of more than 2,500 qualified scientific service providers in a strategic partnership that “levels the playing field” for startups.
Helomics Corporation and Pittsburgh Life Sciences Greenhouse (PLSG) have collaborated to form a biotechnology incubator with a precision and diagnostics medicine focus.
Charles River Laboratories International, Inc. has partnered with OcellO to expand its PDX model capabilities and has made several additions to its online Tumor Model Compendium.
Lonza's biopharma business grew faster than other divisions in 2016 with a drug firm becoming the Swiss life science supplier's biggest customer for the first time since 2013
The Novo Nordisk Foundation has awarded a DKK118m ($17m) grant to fund development of a fermentation pilot plant for cell line scale up experiments at the Technical University of Denmark.
After buying two CMOs, Japanese glassmaker AGC has made “a full-fledged launch” into the biologics manufacturing space and says it will consider further M&A opportunities.
GE Healthcare hopes to increase the yield of biopharmaceuticals made using its Chinese Hamster Ovary (CHO) expression system through a partnership with synthetic biology firm Synpromics.
Acticor Biotech has made a deal with Merck KGaA’s CMO MilliporeSigma to use its Provantage End-to-End services to make its anti-thrombotic antibody fragment ACT-017 for stroke.
ATCC has signed a strategic agreement with the contract research organization (CRO) BioAgilytix as part of its ongoing initiative to provide CRO services.
Novartis has recruited Jacobs to undertake a €100m expansion at a French biomanufacturing facility which will add a second purification line and several cell culture bioreactors.
CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.
A new $60m facility at a MSD site in Ireland will offer Fujifilm Diosynth customers 20,000L of microbial biologics capacity in a collaboration between the two firms.
Lonza plans to expand mammalian cell culture-based drug and viral manufacturing capacity after growth in both businesses helped it to record first quarter sales.
Single-use is the future but stainless steel bioreactors will always play a role in drug production says an expert, who thinks firms could do worse than consult a CMO before deciding in which technology to invest.
The partnership with recombinant protein development firm GTP Technologies will create an end-to-end manufacturing service, speeding up production of monoclonal antibodies and reducing costs, says Novasep.
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
Nasdaq-bound Chinese biopharma BeiGene has chosen GE Healthcare’s Flexfactory platform for the monoclonal antibody (mAb) plant it is building in Suzhou.
